Vascular Therapies Stock

vasculartx.comHealthcare / BioTech & PharmaFounded: 2001Funding to Date: $74.51MM

Vascular Therapies is a late-stage biopharmaceutical company focused on developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.

Register To Buy and Sell Shares

For more details on financing and valuation for Vascular Therapies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Vascular Therapies’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Vascular Therapies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

John McDermott
Chief Executive Officer & Board Member
Paul Barkofsky Ph.D
Vice President, New Product Development
Maureen Harrison
Vice President, Quality Assurance
Sriram Iyer MD
Founder, Chief Scientific Officer & Board Member
Rosanne Terraciano
Vice President, Operations

Board Members

Andrew Midler
Savitr Capital
Kiyoshi Takesue
Robert Flanagan
Dan Ryan
Gerald Dorros MD
The Gerrald Dorros and Myra S. Dorros Recovable Trust
Robert Croce
New Enterprise Associates
Sriram Iyer MD
Allan Tessler
John McDermott
Michael Bamberger
Somasundaram Subramaniam
New Science Ventures

Frequently Asked Questions About Vascular Therapies’ Stock

Can you buy Vascular Therapies’ stock?
Vascular Therapies is not publicly traded on NYSE or NASDAQ in the U.S. To buy Vascular Therapies’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Vascular Therapies’ stock?
Yes, you can sell stock of a private company like Vascular Therapies. Forge can help you sell your Vascular Therapies stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Vascular Therapies’ stock price?
Vascular Therapies is a privately held company and therefore does not have a public stock price. However, you may access Vascular Therapies’ private market stock price with Forge Data.
What is Vascular Therapies’ stock ticker symbol?
Vascular Therapies does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease
/PRNewswire/ -- Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative...
Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]
Updated on: Apr 19, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.